Breaking New Ground in Levodopa-Induced Dyskinesia (LID) in Parkinson’s Disease

Dr. Randall D. Marshall is a psychiatrist and drug-development executive with more than 30 years of experience spanning academic medicine, clinical research, and biopharmaceutical leadership in CNS and rare disease, and has led programs from translational research through Phase 1–3 and post-marketing studies. He is currently Chief Medical Officer of Mentara Therapeutics, a clinical-stage neuroscience company advancing novel treatment for Parkinson’s LID (levodopa induced dyskinesia) and other central nervous system disorders, mediated by the PDE10A inhibitor MTA-304. He previously served as Chief Medical Officer of EuMentis Therapeutics, and Chief Medical Officer and co-founder at Artara Therapeutics, and has served as CMO or clinical development consultant to several early-stage companies. He previously held clinical development leadership roles at Retrophin, Alkermes, Euthymics Bioscience, Neurovance, and Sunovion Pharmaceuticals. At Retrophin, he led development of fosmetpantotenate for the ultra-rare neurodegenerative disease PKAN, advancing the program from first-in-human studies to a pivotal trial with an FDA Special Protocol Assessment in two years.

Dr. Marshall earned his MD at Johns Hopkins University and completed his psychiatry residency at Columbia University, where he attained Associate Professor and was the Director of Trauma Studies and Services at the New York State Psychiatric Institute. While at Columbia he was principal investigator, co-principal investigator or advisor to ~30 research grants funded through NIH, nonprofits and industry, and he has published more than 140 peer-reviewed publications, book chapters or books in his fields of expertise. His academic work focused on PTSD, anxiety disorders, and post-9/11 trauma treatment and training programs.